

# Aladdin J Mohammad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5826928/publications.pdf>

Version: 2024-02-01

65  
papers

2,534  
citations

218381

26  
h-index

205818

48  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2232  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
2	Global epidemiology of vasculitis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 22-34.	3.5	112
3	Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA. <i>Rheumatology</i> , 2022, 61, 3461-3470.	0.9	8
4	FC040: Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Outcomes in a Multicentre Cohort. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
5	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. <i>Kidney International Reports</i> , 2022, 7, 1745-1757.	0.4	3
6	An update on polymyalgia rheumatica. <i>Journal of Internal Medicine</i> , 2022, 292, 717-732.	2.7	27
7	Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , 2021, 60, 2745-2754.	0.9	30
8	Infections Are Associated With Increased Risk of Giant Cell Arteritis: A Population-based Case-control Study from Southern Sweden. <i>Journal of Rheumatology</i> , 2021, 48, 251-257.	1.0	16
9	High risk of coronary artery aneurysm in Kawasaki disease. <i>Rheumatology</i> , 2021, 60, 1910-1914.	0.9	15
10	Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study. <i>Journal of Autoimmunity</i> , 2021, 117, 102579.	3.0	10
11	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	0.9	20
12	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. <i>Rheumatology</i> , 2021, 60, e262-e263.	0.9	0
13	Severe infections in patients with ANCA-associated vasculitis treated with rituximab. <i>Rheumatology</i> , 2021, 61, 205-212.	0.9	6
14	Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate. <i>Rheumatology</i> , 2021, 61, 146-153.	0.9	16
15	Trajectory of Healthcare Resource Utilization in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1307-1313.	1.0	1
16	Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes. <i>Rheumatology</i> , 2021, , .	0.9	6
17	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
18	Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate: reply. <i>Rheumatology</i> , 2021, 60, e423-e424.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , 2021, 60, 4616-4623.	0.9	19
20	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	0.9	22
21	Malignancies in Giant Cell Arteritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 400-406.	1.0	10
22	Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 1229-1237.	1.0	22
23	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020, 47, 580-588.	1.0	5
24	Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1040-1048.	1.6	81
25	Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case-control study. <i>RMD Open</i> , 2020, 6, e001285.	1.8	4
26	International Consensus on Antineutrophil Cytoplasmic Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	2.5	36
27	An update on the epidemiology of ANCA-associated vasculitis. <i>Rheumatology</i> , 2020, 59, iii42-iii50.	0.9	73
28	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3229-3236.	0.9	30
29	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 301-308.	0.4	20
30	158. INCIDENCE AND PREDICTORS OF SEVERE INFECTIONS IN ANCA-ASSOCIATED VASCULITIS IN A POPULATION-BASED COHORT - PRELIMINARY RESULTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
31	159. INFECTIONS ARE ASSOCIATED WITH INCREASED RISK OF MPO- BUT NOT PR3-ANCA-ASSOCIATED VASCULITIS - A POPULATION-BASED CASE-CONTROL STUDY FROM SOUTHERN SWEDEN. <i>Rheumatology</i> , 2019, 58, .	0.9	0
32	164. INCIDENCE AND SEASONAL VARIATION OF BIOPSY-PROVEN GIANT CELL ARTERITIS - REVISITED A 20 YEARS POPULATION-BASED STUDY FROM SWEDEN. <i>Rheumatology</i> , 2019, 58, .	0.9	0
33	165. INFECTIONS ARE ASSOCIATED WITH INCREASED RISK OF GIANT CELL ARTERITIS - A POPULATION-BASED CASE-CONTROL STUDY FROM SOUTHERN SWEDEN. <i>Rheumatology</i> , 2019, 58, .	0.9	0
34	166. PREVALENCE OF BIOPSY-PROVEN GIANT CELL ARTERITIS IN SOUTHERN SWEDEN. <i>Rheumatology</i> , 2019, 58, .	0.9	0
35	271. SEVERE INFECTIONS IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITH RITUXIMAB. <i>Rheumatology</i> , 2019, 58, .	0.9	0
36	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , 2019, 5, e000905.	1.8	66

#	ARTICLE	IF	CITATIONS
37	Epidemiology of primary systemic vasculitis in children: a population-based study from southern Sweden. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 295-302.	0.6	55
38	Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. <i>Rheumatology</i> , 2018, 57, 1309-1310.	0.9	13
39	Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). <i>Rheumatology</i> , 2018, 57, 1400-1407.	0.9	39
40	Brief Report: Rituximab for the Treatment of Adult Onset IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2018, 70, 109-114.	2.9	71
41	Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky026.	0.3	11
42	Hospitalizations due to systemic connective tissue diseases: Secular trends and regional disparities in Sweden, 1998-2016. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1900-1906.	0.9	4
43	P1_144 Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden. <i>Rheumatology</i> , 2017, 56, iii88-iii88.	0.9	0
44	Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. <i>RMD Open</i> , 2017, 3, e000435.	1.8	33
45	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1468-1475.	1.0	47
46	Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype. <i>Journal of Rheumatology</i> , 2017, 44, 1458-1467.	1.0	76
47	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017, 44, 84-90.	1.0	43
48	Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.4	11
49	The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 363.	0.8	37
50	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2016, 43, 1559-1565.	1.0	59
51	Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. <i>Journal of Rheumatology</i> , 2016, 43, 1553-1558.	1.0	38
52	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 993-997.	0.5	100
53	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1128-1135.	2.2	75
54	Takayasu Arteritis in Southern Sweden. <i>Journal of Rheumatology</i> , 2015, 42, 853-858.	1.0	42

#	ARTICLE	IF	CITATIONS
55	Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, i14-i22.	0.4	183
56	Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience. <i>Journal of Rheumatology</i> , 2015, 42, 1906-1913.	1.0	46
57	Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. <i>Nephrology Dialysis Transplantation</i> , 2014, 30 Suppl 1, i23-30.	0.4	8
58	Primary systemic vasculitis with severe $\alpha$ 1-antitrypsin deficiency revisited. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 242-245.	0.6	10
59	A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis Versus Myeloperoxidase ANCA-associated Nephritis. <i>Journal of Rheumatology</i> , 2014, 41, 1366-1373.	1.0	90
60	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. <i>Annals of Internal Medicine</i> , 2014, 160, 73-80.	2.0	133
61	Incidence, prevalence and clinical characteristics of Behçet's disease in southern Sweden. <i>Rheumatology</i> , 2013, 52, 304-310.	0.9	65
62	Association of cigarette smoking with organ damage in primary systemic vasculitis. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 51-56.	0.6	8
63	Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. <i>Rheumatology</i> , 2009, 48, 1560-1565.	0.9	241
64	The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 268-275.	0.6	25
65	Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden. <i>Rheumatology</i> , 2007, 46, 1329-1337.	0.9	232